1. DOP048 Vedolizumab levels during induction are associated with long-term clinical and endoscopic remission in patients with inflammatory bowel disease. (16th January 2018) Authors: Yarur, A; Bruss, A; Fox, C; Beniwal-Patel, P; Patel, A; Berens, B; Naik, S; Stein, D Journal: Journal of Crohn's and colitis Issue: Volume 12:Number 1(2018:Jan.)Supplement 1 Page Start: S064 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P159 Patients with Inflammatory Bowel Disease Present with Lower Trabecular Bone Scores. (27th May 2021) Authors: Yarur, A; Alexandra, B; Beniwal-Patel, P; Stein, D; Nunez, L; Berens, B; Shaina, S; Parakkal, D; Shaker, J; Jenna, S Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S238 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P552 Higher Serum Ustekinumab Levels Correlate With Higher Rates Of Steroid-Free Deep Remission And Endoscopic Healing In Patients With Inflammatory Bowel Diseases. (21st January 2022) Authors: Yarur, A; Ungaro, R; Jain, A; Nunex, L; Spencer, E; Bruss, A; Berens, B; Beniwal-Patel, P; Dervieux, T; Dubinsky, M Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i498 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗